By Olivia Bugault 
 

Merck KGaA said Thursday that it is collaborating with California-based Mammoth Biosciences for the development, scale-up and commercial production of Covid-19 diagnostic tests in the U.S.

The New SARS-CoV-2 test developed by Mammoth could enable performing roughly 1,500 tests per 8-hour shift, the German pharmaceutical and chemicals company said.

"This collaboration will allow us to help Mammoth with the development and production of their new SARS-CoV-2 test, which, once approved by the FDA, will increase testing capacity here in the U.S. at the scale needed to combat this pandemic," the head of Merck's applied solutions, Life Science, said.

Mammoth Biosciences is planning to submit its CRISPR-based tests for FDA emergency use authorization later this year, it said.

 

Write to Olivia Bugault at olivia.bugault@wsj.com

 

(END) Dow Jones Newswires

October 29, 2020 12:40 ET (16:40 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Merck KGaA (PK) Charts.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Merck KGaA (PK) Charts.